Semaglutide Research for Obesity
An evidence-based overview of research examining Semaglutide in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
Semaglutide received FDA approval for chronic obesity management in 2021 based on the comprehensive STEP clinical trial program. The drug achieved substantial weight reduction across diverse populations including those with and without type 2 diabetes. STEP 1 demonstrated that 86.4% of participants achieved clinically meaningful weight loss (5% or more), with 32% achieving 20% or greater reduction. The STEP-HFpEF trial showed benefits in obese patients with heart failure with preserved ejection fraction. SELECT (N=17,604) found a 20% relative reduction in its major adverse cardiovascular-event composite among adults with overweight or obesity, established cardiovascular disease, and no diabetes. Wegovy injection subsequently gained a US cardiovascular risk-reduction indication for adults meeting its labeled population criteria.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.